Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK CITY and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with...
-
NEW YORK, and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with...
-
NEW YORK and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with...
-
NEW YORK CITY and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with...
-
WASHINGTON, D.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The United States Mint (Mint) will begin accepting orders for the 2026 American Eagle One Ounce Silver Proof Coin (W) (product code 26EA)...
-
Charleston, SC, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Does God See My Tears? is a heartwarming children's tale that captures the emotional journey of Amanda, a ten-year-old girl facing a serious heart...
-
DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of...
-
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut...
-
New York City, NY, Feb. 22, 2026 (GLOBE NEWSWIRE) -- Across the United States, digital healthcare platforms are transforming how patients begin medically supervised treatment programs. Providers...
-
Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111